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Abstract
Purpose Vogt–Koyanagi–Harada (VKH) disease is
a primary autoimmune stromal choroiditis. Aim of the
study was to gather a body of evidence from the
literature and from experts that systemic corticosteroid
combined with non-steroidal immunosuppressive
therapy should become the standard of care in
initial-onset VKH disease.
Methods Literature was reviewed and leading
experts in VKH were consulted in different parts of
the world in order to put forward a consensus attitude
in the management of initial-onset VKH disease.
Results There was a substantial body of evidence in
the literature that early aggressive and sustained
corticosteroid and non-steroidal immunosuppressive
therapy in initial-onset VKH disease allows to achieve
full control of choroidal inflammation, eliminating any
subclinical choroidal inflammation, and substantially
reduces recurrences with improvement of anatomical
and functional outcomes. This was in agreement with
experts’ opinion and practice. ICGA was the method
of choice to monitor disease evolution.
Conclusion Since the choroidal space is easily
accessible to systemic therapy and because inflamma-
tion in VKH disease is exclusively originating from
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the choroidal stroma, early and sustained treatment
right at the onset of the disease process with dual
corticosteroid and non-steroidal immunosuppressive
therapy can result in full ‘‘healing’’ in many cases
preventing sunset glow fundus which results from
depigmentation from chronic uncontrolled
inflammation.
Keywords Vogt–Koyanagi–Harada disease 
Stromal choroiditis, autoimmune disease 
Granulomatous uveitis  Indocyanine green
angiography  Immunosuppressive therapy
Introduction
Vogt–Koyanagi–Harada (VKH) disease is a bilateral
granulomatous panuveitis with exudative retinal
detachments [1] found to be caused by an autoimmune
reaction against stromal melanocyte-associated pro-
teins [2–5]. In the acute phase, ocular disease is
classically associated with inflammation of the
meninges (cerebrospinal fluid mononuclear pleocyto-
sis) and dysacusis [6, 7]. The initial-onset acute
disease typically exhibits granulomatous choroiditis
with exudative retinal detachment and optic disc
hyperemia and swelling, subsequently involving the
anterior segment and finally developing into chronic
recurrent granulomatous anterior uveitis if not prop-
erly treated, with typical ‘‘sunset glow fundus’’ (SGF)
[8–10], as well as persisting meningitis, persisting
auditory disturbances as well as integumentary
changes (vitiligo, alopecia and poliosis) [11].
Knowing the disease mechanism is the key to its
management: VKH is a primary stromal
choroiditis
At the start of disease, patients may complain of
headaches (a precious diagnostic element very often
present), nausea, vertigo, fever, meningismus scalp
hypersensitivity and orbital pain [12, 13]. This first,
prodromal stage of disease is usually lasting for a few
days/weeks and corresponds at the ocular level to
subclinical inflammation starting exclusively in the
choroidal stroma, without any other ocular clinical
sign to indicate the presence of the inflammatory
process, which can only be identified at this stage by
performing indocyanine green angiography (ICGA)
[14]. (Fig. 1).
Subsequently, the disease becomes clinically
apparent when choroidal inflammation spills over,
usually in a cataclysmic fashion into the neighbouring
structures including the optic disc, the retina, the
ciliary body and sometimes also the anterior chamber.
The expression of the disease in this second, uveitic/
exudative stage of the disease, is that of a bilateral
mostly granulomatous panuveitis with predominantly
posterior involvement [9, 10, 15]. Classical clinical
signs are bilateral papillitis, bilateral serous detach-
ments of the retina, limited to moderate vitritis and
sometimes an anterior usually granulomatous uveitis
with minimal to moderate anterior chamber flare and
cells associated with small to mid-size granulomatous
keratic precipitates (KPs) [9, 10, 15]. (Fig. 2) At
disease onset, the anterior uveitis can initially be non-
granulomatous. Sometimes the degree of intraocular
inflammation is such, in early acute disease, that there
is supraciliary fluid accumulation at the origin of a
ciliary detachment causing myopisation and some-
times angle-closure glaucoma [15].
In initial-onset acute disease, the most severe
involvement occurs posteriorly. It is of utmost
importance to be aware of the fact that the initial
inflammatory event is taking place in the uvea
starting in the choroid and more precisely in the
choroidal stroma, the primary origin of all inflam-
mation, hence the name of primary stromal
choroiditis [16]. The other structures such as the
retina and optic disc involved during the acute,
clinically apparent phase of disease, are only
involved secondarily to the choroidal inflammatory
reaction. Inflammation in these structures is merely
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Fig. 1 During the prodromal stage of the disease, subclinical
choroidal inflammation is silently developing in the choroidal
stroma as shown on cartoon (top left). This subclinical choroidal
involvement can only be detected by ICGA, possibly by
choroidal OCT. On the fundus pictures shown on top right,
the right fundus is discoloured yellow due to massive choroidal
infiltration. The right fundus looks normal and this patient was
diagnosed as ‘‘unilateral’’ VKH disease. FA shows no lesions
(six bottom left frames) but ICGA (six bottom right frames)
clearly shows numerous hypofluorescent dark dots (HDDs)
indicating choroidal granulomas in the apparently uninvolved
eye
Fig. 2 Acute exudative
initial-onset VKH disease.
Peripapillary and retinal
exudative detachments seen
on fundoscopy (top left) and
FA (bottom left).
Extrachoroidal structures
are involved when choroidal
disease spills over to
neighbouring structures
(cartoon, top right). Optical
coherence tomography
(OCT) shows clearly the
detachment of the
neurosensory retina (middle
figure on the right).
Moderate granulomatous
anterior uveitis
accompanying posterior
involvement. (bottom right)
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the consequence of the choroiditis; they do not
generate inflammation by themselves [17].
Therefore, the first element that should determine
our approach to the management of VKH disease is the
fact that the single and exclusive source of all
intraocular inflammation comes from the choroidal
stroma. This makes VKH disease unique when
compared to other choroiditis entities such as sar-
coidosis which involves both choroid and retina at
random [18] or birdshot retinochoroiditis where there
is dual, parallel, independent choroidal and retinal
involvement [19]. Hence management in VKH disease
should be principally aimed at the choroidal inflam-
mation with subsequent resolution of all intraocular
inflammation. The choroid being a highly vascularized
structure is very accessible to systemic treatment, and
there is no rationale for intravitreal therapy which, as
expected, has been shown not to be very efficient [20].
Isolated cases advocating intraocular corticos-
teroids have been published but do not represent a
serious argument, one of these cases not even being a
VKH case [21].
The essential role of indocyanine green
angiography (ICGA) in the appraisal
and management of VKH (Figs. 3, 4, 5)
As the initial inflammatory events start in the
choroidal stroma, ICGA is indeed the method of
choice to establish and monitor choroidal inflamma-
tion [22, 23]. In that respect, ICGA is able to detect
early subclinical disease as well as subclinical recur-
rences during tapering of therapy [24]. ICGA was also
able to show occult concomitant choroidal inflamma-
tion during anterior segment recurrence when there
seemingly was no posterior uveal activity [25].
ICGA is therefore essential in the investigation and
follow-up of VKH disease as it brings additional
global panfundal information on the crucial, core
structure of the disease process, that is not available
otherwise. Depth-enhanced choroidal optical coher-
ence tomography of the choroid (EDI-OCT), which
shows choroidal thickening, is not capable of provid-
ing reliable short-term monitoring regarding the full
inflammatory control of the disease in the choroid to
adjust therapy, which can be achieved with ICGA
[26]. (Fig. 3) However, OCT measurement of
choroidal thickness is a good parameter to follow
choroidal disease in the long-term [27].
Classical ICGA signs in VKH disease have now
been well established. In a Caucasian group of
patients, 4 signs consistently found in acute VKH
disease have been identified, the most important one
being hypofluorescent dark dots (HDDs) indicating
stromal foci (granulomas) [22]. (Fig. 4) The three
other ICGA signs consistently found and useful for the
evaluation and follow-up of choroiditis were early
hyperfluorescent choroidal vessels, fuzzy indistinct
large choroidal vessels indicating choroidal vasculitis
and ICGA disc hyperfluorescence [22]. (Fig. 4) A
further study showed that these ICGA signs were also
present in Japanese patients and a recent study showed
the same in Saudi Arabian patients, indicating that
these are universally found signs [28, 29].
ICGA signs were seen in 100% of initial-onset,
untreated disease and the first sign to respond to
therapy was disc hyperfluorescence [22, 24]. In acute
recurrent attacks during the chronic stage of disease,
the same signs can be observed. However, in chronic
smouldering disease without acute recurrent attacks,
only hypofluorescent dark dots (HDDs) and fuzzy
indistinct choroidal vessels indicate ongoing choroidal
inflammation [22].
Furthermore, it was shown that ICGA was most
appropriate for close follow-up of VKH disease,
promptly showing subclinical and occult choroidal
recurrence of the disease [24]. It also seems to be the
most reactive monitoring parameter compared to
choroidal OCT less reliable for close follow-up as
illustrated in the case shown on Fig. 5. Heidelberg
enhanced depth imaging optical coherence tomogra-
phy (EDI-OCT) or other choroidal OCTs have clearly
shown choroidal thickening in VKH disease and
progressive decrease of choroidal thickness during
treatment and on long-term follow-up [27, 30].
Although thickness is proportional to treatment course
and its linear decrease can be clearly documented by
choroidal OCT, these changes occur more slowly over
time and are less reactive and sensitive to be relied
upon for close follow-up [31].
Based on the evidence presented, the second
element to be taken into account for optimal manage-
ment of VKH disease is that ICGA monitoring is
essential for precise follow-up of the disease and to
verify the absence of occult choroiditis.
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Rationale for improved management of VKH
disease
The principles of therapy of VKH disease are to
suppress the initial intraocular inflammation in the
acute posterior uveitic/exudative stage with early and
aggressive use of systemic corticosteroids followed by
slow tapering. Such treatment may shorten the dura-
tion of the disease, may prevent progression into the
chronic stage, and may also reduce the incidence of
extraocular manifestations [1]. The intraocular inflam-
mation will proceed to recurrent granulomatous ante-
rior uveitis with typical SGF if not properly treated
[1, 9, 10]. Despite proper treatment with corticosteroid
monotherapy, several studies reported the develop-
ment of chronic smouldering and/or recurrent granu-
lomatous inflammation and sunset glow fundus (SGF)
with peripapillary atrophy and depigmented small
atrophic lesions at the level of retinal pigment
epithelium [10, 32].
Recently, Sakata et al. reported a high rate of
clinical recurrence in VKH patients treated with early
high-dose corticosteroids given within 30 days from
disease onset and slow taper, as 79% of patients
progressed to chronic recurrent disease and 38%
developed subretinal fibrosis [33]. Similarly, Chee
et al. observed that one-third of patients receiving
high-dose corticosteroid therapy within 2 weeks of
onset progressed to chronic recurrent disease [34].
Keino et al. demonstrated that despite high-dose
corticosteroid therapy at initial onset, 17.5% of
patients developed chronic ocular inflammation [35].
Chronic recurrent VKH disease is significantly asso-
ciated with more severe anterior segment inflamma-
tion at presentation and a worse visual acuity [10] and
a worse mean retinal sensitivity [36] compared with
initial-onset acute VKH disease receiving appropriate
therapy [10]. Studies using laser flare cell photometry
demonstrated that both aqueous flare values and cell
counts were significantly higher in patients with
chronic recurrent VKH disease than those with
initial-onset acute VKH disease [37]. Furthermore,
chronic recurrent granulomatous inflammation in the
anterior segment was more refractory to treatment
Fig. 3 Sensitivity and
global panfundal
information given by ICGA.
Case of VKH disease
responsive to initial highly
dosed corticosteroids with
peripheral recurrence under
mycophenolic acid
(Myfortic ) and
cyclosporine (CsA)
characterized by numerous
HDDs (top pictures). After
introduction of infliximab
complete resolution of
choroiditis within 5 weeks
(bottom pictures),
establishing infliximab as
the therapy to which this
patient was responsive.
Posterior pole involvement
was minimal and choroidal
OCT did not reflect
spectacular improvement of
choroiditis
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[36]. Consequently, complications are more common
in patients with chronic recurrent VKH disease who
present recurrent granulomatous anterior uveitis and
SGF [9, 10].
The poor visual prognosis associated with chronic
ocular inflammation and the well-documented ocular
and systemic complications of long-term high-dose
corticosteroid use have led many experts to suggest
initiating first-line non-steroidal immunosuppressive
therapy using cyclosporine, azathioprine, methotrex-
ate, mycophenolate mofetil or other, combined with
systemic corticosteroids early in the course of care of
patients to achieve better control of the uveitis and to
facilitate earlier tapering of corticosteroids [38–40].
Standard treatment regimens recommend high-
dose systemic corticosteroid therapy, with or without
intravenous administration during the first 3 days of
treatment, tapered over a period of 6–9 months
[1, 41–44]. While there is a universal consensus on
the treatment of the acute phase of VKH disease where
high-dose corticosteroids are necessary to quickly
bring inflammation under control, this is not the case
for the post-acute phase of the disease [45].
It has now been clearly shown by ICGA monitoring
of the choroid during tapering of corticosteroids that
active choroidal inflammation can be identified in an
apparently quiescent eye explaining the chronic evo-
lution [23–26, 45]. This shows that the standard
recommended therapy is indeed suppressing clinically
apparent disease but is insufficient to suppress
choroidal ICGA detected inflammation [45]. This
has led some experts to maintain sufficient therapy
including first-line non-steroidal immunosuppressive
drugs in the subacute phase and during the tapering
process in order to eradicate choroidal inflammation
[24, 38–40].
Following the administration of corticosteroid
monotherapy tapered over 6–9 months, except for
the rare cases that respond to this simple and relatively
short corticosteroid therapy classically applied, evo-
lution is unfortunately mostly unfavourable [33]. Even
if early and high doses are given, evolution is
Fig. 4 Indocyanine green
angiographic signs. ICGA is
the only technique to
analyse choroidal
inflammatory signs
including early stromal
hyperfluorescent vessels
(top left), hypofluorescent
dark dots (HDD) indicating
choroidal granuloma (top
right), fuzzy indistinct
choroidal vessels (top 2
frames of bottom left
quartett). After 3 days of
intravenous 1000 mg daily
methylprednisolone the
normal pattern of vessels is
again recognizable (bottom
2 frames of bottom left
quartett). Bottom right
quartett of frames shows
diffuse late
hyperfluorescence and
hyperfluorescent inflamed
disc
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characterized by chronic smouldering and/or recurrent
disease, the third, chronic, stage of the disease, after
the prodromal stage and the uveitic/exudative stage
[33].
In smouldering disease, subclinical evolution of
choroidal inflammation has been clearly documented
with the help of ICGA [22–24, 45], explaining the
development of SGF despite (usually suboptimal)
therapy, resulting from the progressive loss of stromal
melanocytes because of an ongoing insufficiently
controlled immunological process [33, 45, 46]. Further
evidence for the presence of smouldering choroiditis is
the low grade intraocular inflammation found by laser
flare photometry in a seemingly quiet eye [37].
As the disease process begins to wane, the posterior
portion of the globe characteristically shows depig-
mentation (Fig. 4). This SGF, reflecting the stromal
pigment loss, has been described to reach high
proportions in most studies and is said to be more
pronounced in Asian patients probably because their
choroid is more heavily pigmented [35, 47, 48].
Keino et al. followed 102 patients with VKH
disease from initial-onset who were treated with high-
dose corticosteroid therapy. SGF developed in 67.6%
of patients. The mean duration until appearance of
SGF was 4.2 ± 2.7 months [49]. Similarly, Lai et al.
demonstrated the development of SGF in 51.4% of
patients who received oral corticosteroids during the
first attack of VKH disease [43]. Several studies
reported the significant association between the inci-
dence of chronic ocular inflammation and the devel-
opment of SGF [10, 35, 50].
SGF is today still presented as the natural course of
the disease which was indeed the case at the time when
no treatment was available, as described by Koyanagi
in the first large series published [51]. To date with the
availability of corticosteroids and immunosuppressive
drugs, SGF is the result of insufficient treatment that is
bFig. 5 A ICGA is more reactive than EDI-OCT for close, visit
by visit follow-up. Patient with initial onset VKH disease having
responded to initial high-dose IV and then oral corticosteroids,
together with mycophenolic acid Myfortic and cyclosporine
(CsA)with reduction of ICGA score from 31/40 to 6/40 (a),
using an established dual FA/ICGA scoring system [61, 62].
Under Myfortic and CsA, ICGA score increased again to 17/40
(b), not reflected in EDI-OCT that shows slight decrease of
choroidal thickness (c, d). B Indocyanine green angiography is
more reactive than EDI-OCT for precise follow-up of VKH
disease (same patient as in Fig. 3) Patient with VKH disease
under Myfortic and CsA to which choroiditis is not responding
with an ICGA score of 20.5/40 (a). After 6 months, it was
decided to add Remicade (Infliximab, an anti-TNF-blocker,
5mg/kg per infusion). 5 weeks later (3 infusions), HDDs
completely disappeared with a decrease of ICGA score from
20.5 ± 4.9 to 1 (p\0.03) (b), while choroidal thickness showed
a slight non-significant difference, 507 ± 66 versus 460 ± 18
lm (p = 0.31) (c, d)
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unable to stop choroidal inflammation but should not
be considered any more as the unavoidable evolution
of VKH disease [52].
Chronic disease can also present with recurrent
acute inflammatory attacks complicating the smoul-
dering evolution, a proof that there are glowing
embers in the choroid ready to flare up again
[23–25, 47]. These acute recurrent attacks resemble
the acute de novo, initial disease with some differ-
ences. The characteristics of the recurrence will
depend on how important the loss of stromal choroidal
melanocytes was during the initial acute attack of the
disease and the subsequent smouldering phase of
disease. If the loss of melanocytes was important,
naturally the preponderant part of the recurrent
inflammation will be anterior as it is classically
described because this is where the bulk of remaining
melanocytes is [9]. However if the loss of choroidal
stromal melanocytes was scarce, recurrences can
present themselves again as predominantly posterior,
which is usually less pronounced than in de novo-
initial disease. Anterior granulomatous uveitis is a
more prominent feature in depigmented fundi with its
classical signs of granulomatous KPs, often pig-
mented, that can even take a mutton-fat aspect,
Koeppe fluffy nodules, diffuse iris infiltration or
Busacca nodules in the iris and posterior synechiae
[10] (Fig. 6). Sometimes, what seems to be a purely
anterior recurrence is associated with a subclinical
posterior recurrence only shown by resurgence of
hypofluorescent dark dots (HDDs) on ICGA [24].
The high proportion of cases with chronic evolution
even with early high-dose corticosteroid therapy
should lead the clinician to the conclusion that the
present standard treatment relying principally on
corticosteroids tapered during 6–9 months is insuffi-
cient and represents the third main consideration in the
design of an optimized management of VKH disease
[33].
Proposals for an optimized management of VKH
disease
The following elements should be considered when
designing an improved management for VKH disease:
(1) VKH is a primary stromal choroiditis where
inflammation is exclusively originating from the
choroid, meaning that as soon as choroiditis is
eradicated intraocular inflammation is over; (2)
henceforth the principal parameter for disease moni-
toring is ICGA; (3) the presently recommended
standard therapy for VKH disease, based on systemic
corticosteroids given for 6–9 months, is insufficient
and treatment should be stepped-up [38].
We know by now that, when clinically apparent
disease is brought under control, this is not sufficient in
most cases. ICGA monitoring of VKH patients under
treatment has shown that once clinical signs and
functional parameters including fundus picture, OCT,
FA and visual acuity have normalized, choroidal
inflammation is still present and evolving as evidenced
by ICGA [22–24, 47]. The persistence of choroidal
subclinical disease explains the evolution towards
Fig. 5 continued
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SGF in most cases receiving standard therapy
[35, 48, 49].
Taking into account these elements, therapy of
VKH disease should have two main phases including
(1) treatment of the early uveitic/exudative acute stage
of the disease and (2) maintaining sufficient therapy
including first-line non-steroidal immunosuppressive
drugs long enough leading to resolution of choroidal
inflammation, if possible using ICGA assisted taper-
ing of therapy.
Treatment of the early acute phase of disease
The severity of acute VKH disease needs high-dose
corticosteroids given as early as possible [53]. A
3 days course of intravenous methyl-prednisolone
(500–1000 mg per day) is recommended, followed
by high-dose oral prednisone (1.0–1.2 mg/kg) for
4–6 weeks. Although the need for intravenous corti-
costeroid administration during the 3 first days of
treatment has not really been proven, common sense
has it that, in case of hyperacute uveitis, rapid
resolution of inflammation is desirable [54].
Subacute phase of therapy, corticosteroid tapering
& discontinuation of therapy
It was shown, using ICGA-monitoring of choroiditis,
that in 7/9 patients an immunosuppressive agent had to
be added because of recurrent choroidal disease seen
Fig. 6 Signs found in
chronically evolving
disease. Chronic
granulomatous uveitis with
old pigmented KPs (top
left), Koeppe nodules, iris
infiltration and Busacca
nodules (top right). Mid-
periphery hypopigmented
lesions are shown on the
middle left picture and
sunset-glow-fundus on the
right middle picture.
Mottled irregular, disturbed
RPE in the posterior pole
and high-water marks
indicating limit of
reattached serous retinal
detachment as well as disc
hyperfluorescence seen on
the FA frame (bottom left).
Only ICGA can show that
disease is still active as
evidenced by the numerous
dark dots (bottom right)
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during ICGA follow-up [24]. It therefore makes sense
to add a non-steroidal immunosuppressant directly at
the start of disease with the risk of overtreating some
patients that would have responded to corticosteroids
alone. Early introduction of non-steroidal immuno-
suppressive therapy is also indicated because the same
study showed that the mean duration of therapy
needed for choroiditis-free resolution of disease was
27 months, a duration precluding the use of corticos-
teroids alone [24]. In case of resolution of choroidal,
ICGA monitored, inflammation, tapering down of
prednisone to low levels (5–10 mg daily) should be
tried within a period of ±4 months, a time-span
needed for some immunosuppressants like azathio-
prine or mycophenolate to reach full activity [38]. An
immunosuppressant increasingly chosen by clinicians
is mycophenolate mofetil (CellCept, 1000 mg twice
daily) or mycophenolic acid (Myfortic, 720 mg
twice daily) because this agent is both very effective
and usually well tolerated. Other immunosuppressing
drugs or biologic agents that have been reported are
cyclosporine, anti-TNF agents or interferon-alpha,
noting for the latter that it can itself induce VKH
disease [55, 56].
Abu El-Asrar et al. evaluated the effectiveness of
mycophenolate mofetil as first-line therapy combined
with systemic corticosteroids in initial-onset acute
uveitis associated with VKH disease [38]. They
compared the outcomes in this group with those of
another group of patients with acute uveitis associated
with VKH disease who were treated with corticos-
teroid monotherapy or with delayed addition of
immunomodulatory therapy. The outcome of this
group was previously reported [32]. They demon-
strated that the use of mycophenolate mofetil as first-
line therapy combined with systemic corticosteroids
was safe and effective in the treatment of acute uveitis
associated with VKH disease. It has marked corticos-
teroid-sparing effect and significantly reduced the
development of chronic recurrent inflammation and
late complications. In addition, mycophenolate mofe-
til significantly improved visual outcome. None of the
patients developed SGF, suggesting that it was effec-
tive in controlling progressive subclinical choroidal
inflammation. Furthermore, mycophenolate mofetil
was effective in preventing the development of
vitiligo, poliosis, alopecia, and sensory hearing loss
[38].
Some authors proposed ICGA-monitoring of
regression of choroidal disease in the convalescent
phase of disease and long-term tapering of inflamma-
tion suppressive therapy until absence of recurrence of
choroidal disease (zero tolerance of choroiditis).
Meaningful ICGA-monitoring presupposes an ICGA
every 5–6 weeks during the first 4–5 months and then
every 2–3 months during the long-term tapering
period but there are cost considerations [24]. Perform-
ing an ICGA every 6 months in the follow-up of VKH
disease cannot be called ICGA-monitoring but repre-
sents merely ICGA documented follow-up as the low
frequency of ICGAs performed in this study did not
allow to modify treatment in a timely fashion [57].
During the tapering phase of corticosteroids and in the
convalescent phase when corticosteroids have been
stopped, in case of ICGA detected recurrence of
subclinical choroidal disease, corticosteroids (oral
prednisone) should be re-increased or introduced
again to 1 mg/kg for a few days followed by a new
taper. Sneaking out with treatment takes much longer
than the treatment durations reported in textbooks or in
published literature, until successful tapering without
subclinical disease recurrence in the choroid is
achieved. In a series of 9 patients treated with
ICGA-assisted management, the mean duration of
treatment was 27.3 months ±38.2 months (range
9–114) which is much longer than the 6 to 9 months
cited in the literature [24]. The advantage of such a
relentless therapy is a high proportion (7/9 cases, 78%)
of 00healed00 cases with no recurrent activity within a
mean follow-up period without therapy of
26 ± 14.8 months as well as a low proportion of
cases with sunset glow fundus (3/9, 33%) [24]. These
results indicate that early and sustained, ICGA-
monitored treatment is able to modify the phenotype
of VKH disease. A similar achievement with sustained
and prolonged immunosuppressive therapy was
achieved in birdshot retinochoroiditis, another stromal
choroiditis where the development of oval depig-
mented birdshot lesions could be totally suppressed
and the phenotype of the disease was changed by
radical therapy [58].
Some authors, in stromal choroiditis, increasingly
use early high-dose systemic steroids at start associ-
ated with a quickly acting immunosuppressive drug
such as cyclosporine together with a well-tolerated
immunosuppressant such as mycophenolic acid which
1392 Int Ophthalmol (2017) 37:1383–1395
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needs several months to be fully active [59]. This
allows more rapid tapering of corticosteroids and a
limited period (4–5 months) of cyclosporine use.
At this point, further studies are looking into the
need for non-steroidal immunosuppression for ini-
tial-onset disease. In Brazil, a study on nine patients
with initial-onset disease treated with highly dosed
corticosteroids showed that all presented recurrence
of inflammation after 6 months after onset of
disease, either detected clinically or subclinically,
in a median time of seven months or when the
tapering dose of oral corticosteroids was reduced to
0.3 mg/kg/day. It seems that, considering this
prospective study, even treatment with highly dosed
corticosteroids with a really slow tapering was
insufficient to prevent further recurrences and the
protocol was changed to early non-steroidal
immunosuppression [60]. In Japan, at present, two
multicentre trials are being conducted to assess the
effect of early non-steroidal immunosuppressive
therapy in addition to corticosteroids in initial-onset
acute VKH disease. Together with the evidence
presented here, this shows that there is a clear trend
towards the association of non-steroidal immuno-
suppressive therapy and corticosteroids in the man-
agement of initial-onset VKH disease.
Perspective and concluding remarks: sunset-glow
fundus is no more a fatality
VKH disease is a primary stromal choroiditis, mean-
ing that inflammation takes its origin exclusively in the
choroid, reaching other structures only when inflam-
mation spills over to these compartments. Unlike in
birdshot retinochoroiditis, where inflammation starts
independently in the choroid and at the level of the
retina, in VKH disease, inflammation initiates
nowhere else than in the choroid which is the structure
that should be targeted by therapy. The choroidal
compartment, unlike the retina, is easily accessible to
systemic therapy. This is the reason why there is
increasing evidence that, if treatment is conducted
consequently with a zero tolerance to recurrence of
choroiditis that can be detected by ICGA or choroidal
OCT, a substantial proportion of cases can be healed
before depigmentation occurs, meaning that sunset-
glow fundus should no more be an inevitable outcome.
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